Development of a Novel First-in-Class Biologic Succinate Modulation Therapy for Crohn’s Disease

Purpose and goal

The aim of the project is to develop a new treatment for Crohn´s disease through the enzyme EngiSD1. The goal is to slow down the disease progression early by reducing excess succinate, restoring the intestinal microbial balance and suppressing inflammation. The project thus contributes both to increased quality of life for patients and to a more sustainable use of resources in healthcare.

Expected effects and result

The project is expected to result in a preclinical data package that will take EngiSD1 further towards clinical trials. In the long term, this could provide patients with Crohn´s disease with early and targeted treatment that reduces the need for surgery and costly biologics. The effect will be improved quality of life for patients, reduced burden on healthcare, and a more cost-effective and sustainable treatment strategy for society.

Planned approach and implementation

The project is based on a systematic development of EngiSD1, from optimization of the enzyme´s stability and function to validation in relevant preclinical models. Through improved bioprocess we can ensure scalable and cost-effective production. The development of new animal models enables reliable efficacy studies and strengthens the foundation for a future clinical trial that can provide long-term benefits for patients and healthcare.